Condition: Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis · Sponsor: Xiang Gao
Inflammatory Bowel Disease (IBD), which encompasses ulcerative Colitis (UC) and Crohn's Disease (CD), has seen significant improvements in patient outcomes with biologic treatments. However, nearly half of the patients are either primary or secondary non-responders to the existing biologics. Upadacitinib is the only oral small molecule targeted drug approved for IBD in China. There is a paucity of research on the efficacy and safety of upadacitinib in treating Chinese patients with UC and CD, and a lack of study data on the Chinese IBD population. This study aims to conduct a multicenter, single-arm, prospective, observational real-world study to analyze the efficacy and safety of upadacitinib in the treatment of Chinese patients with IBD, providing a basis for clinical decision-making.
This description comes directly from the study's public registry record.
Lang Lin · +86-020-38663423 · linlang3@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | Guangzhou, Guangdong, China | Recruiting |
| Sixth Affiliated Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Meizhou People's Hospital | Meizhou, Guangdong, China | Recruiting |
| The Eighth Affiliated Hospital, Sun Yat-Sen University | Shenzhen, Guangdong, China | Recruiting |
| Liuzhou People's Hospital | Liuzhou, Guangxi, China | Recruiting |
| Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine | Nanning, Guangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06780683